References

Itzykson, Raphael, Valeria Santini, Sylvain Thepot, et al. 2023. “Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.” Journal of Clinical Oncology 41 (10): 1888–97. https://doi.org/10.1200/jco.22.00437.

Knuth, Donald E. 1984. “Literate Programming.” Comput. J. (USA) 27 (2): 97–111. https://doi.org/10.1093/comjnl/27.2.97.

Leach, Craig, Laura Bertoldi, Sofia Carbajosa, et al. 2024. “Ex-Vivo Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Acute Myeloid Leukemia.” Blood 144 (Supplement 1): 1380–80. https://doi.org/10.1182/blood-2024-209323.

Merlevede, Jane, Nathalie Droin, Tingting Qin, et al. 2016. “Mutation Allele Burden Remains Unchanged in Chronic Myelomonocytic Leukaemia Responding to Hypomethylating Agents.” Nature Communications 7 (1). https://doi.org/10.1038/ncomms10767.

Robin, Marie, Liesbeth C. de Wreede, Eric Padron, et al. 2022. “Role of Allogeneic Transplantation in Chronic Myelomonocytic Leukemia: An International Collaborative Analysis.” Blood 140 (12): 1408–18. https://doi.org/10.1182/blood.2021015173.

Tefferi, Ayalew, Saubia Fathima, Maymona Abdelmagid, et al. 2025. “BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia.” Blood Journal, ahead of print, May 7. https://doi.org/10.1182/blood.2024027170.

Turunen, Brandon, Craig Leach, Matthew Smith, et al. 2024. “Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia.” Blood 144 (Supplement 1): 2771–71. https://doi.org/10.1182/blood-2024-209024.